Serina Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on November 7, 2025. Serina Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Huntsville, Alabama.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to and approved by stockholders:
- Proposal 1: Election of Directors
- Steve Ledger: 4,165,885 votes For; 93,287 votes Withheld.
- Karen J. Wilson: 4,169,893 votes For; 89,279 votes Withheld.
- Both nominees were elected to serve until the 2028 Annual Meeting.
- Proposal 2: Ratification of Auditors
- Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the 2025 fiscal year.
- Votes: 6,544,850 For; 377,827 Against; 17,636 Abstain.
- Proposal 3: Convertible Note and Warrants
- Approval was granted for the issuance of common stock in connection with the exercise of the Convertible Note and Warrants.
- Votes: 4,149,038 For; 108,481 Against; 1,653 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the terms and dilution impact of the Convertible Note and Warrants approved in Proposal 3.
- Confirm the tenure of the newly elected directors (Steve Ledger and Karen J. Wilson) through 2028.
- Review the full Proxy Statement referenced in the filing for detailed descriptions of the Convertible Note and Warrants proposal.